Table 4.

Predictors of nephrotoxicity in patients of colistimethate sodium and polymyxin B groups

Variables	CMS (n=108)		PMB (n=54)
	OR (95% CI)	P	OR (95% CI)	P
Age ≥65 years	0.76 (0.20–2.95)	0.689	4.13 (0.38–45.10)	0.245
APACHE-II score ≥20	1.00 (0.22–4.45)	0.995	14.40 (1.80–115.31)	0.012
Baseline creatinine clearance <60 mL/min	0.49 (0.04–6.33)	0.585	0.21 (0.01–6.27)	0.365
Baseline creatinine >1.5 mg/dL	0.18 (0.01–2.44)	0.197	0.34 (0.01–9.56)	0.527
BMI ≥30 kg/m2	0.55 (0.06–4.88)	0.593	13.78 (0.08–24.27)	0.320
Concomitant nephrotoxic agents	0.89 (0.07–11.13)	0.928	0.04 (0.00–1.33)	0.072
Diabetes present	1.96 (0.50–7.67)	0.334	2.12 (0.20–22.94)	0.538
10-year survival estimate <50%	0.41 (0.11–1.53)	0.183	0.29 (0.02–4.22)	0.362

CMS=Colistimethate sodium, PMB=Polymyxin B, BMI=Body mass index, APACHE-II=Acute Physiology and Chronic Health Evaluation II, OR=Odds ratio, CI=Confidence interval